Immix Biopharma, Inc. (IMMX)
Automate Your Wheel Strategy on IMMX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMMX
- Rev/Share 0.0032
- Book/Share 0.1552
- PB 14.6921
- Debt/Equity 0.2241
- CurrentRatio 1.2313
- ROIC -4.1828
- MktCap 65741771.0
- FreeCF/Share -0.4496
- PFCF -4.8765
- PE -2.956
- Debt/Assets 0.0667
- DivYield 0
- ROE -2.0535
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Immix Biopharma Announces Other Serious Diseases Strategy
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 …
Read More
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We …
Read More
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18 clinical trial sites in its national footprint.
Read More
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Immix Biopharma Attends FDA CEO Forum in Washington DC
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D.
Read More
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
Read More
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update.
Read More
About Immix Biopharma, Inc. (IMMX)
- IPO Date 2021-12-16
- Website https://www.immixbio.com
- Industry Biotechnology
- CEO Ilya Rachman MBA,
- Employees 18